Male andropause: A myth or reality

Medical Journal Armed Forces India

Volumn 64, Issue 3, 2008, Pages 244-249

  Nandy, Priya Ranjan ^a   Singh, D V ^c   Madhusoodanan, P ^b   Sandhu, A S ^a  

^a Classified Specialist Pediatrics and Pediatric Nephrology   (India)

^b DGMS   (India)

^c BASE HOSPITAL   (India)

Author keywords

Aging male; Andropause; Testosterone replacement therapy

Indexed keywords

ANDROGEN; MESTEROLONE; METHYLTESTOSTERONE; PROVIRON RESTORE; TESTODREM; TESTOGEL CERNOS; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

AGING; ANDROGEN DEFICIENCY; ANDROPAUSE; CLIMACTERIUM; DRUG CHOICE; DRUG HALF LIFE; DRUG IMPLANT; DRUG INDICATION; DRUG PREFERENCE; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; LIVER TOXICITY; MALE; REVIEW; SIDE EFFECT; SKIN IRRITATION; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT;

EID: 50449088530     PISSN: 03771237     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0377-1237(08)80105-0     Document Type: Article

References (29)

1. Charubala Ammuncio. Adams Eventide. Outlook 2005 Feb 14; 60-5.
2. Tan RS, Pu SJ. Is it andropause? Recognizing androgen deficiency in aging men. Postgrad Med 2004; 115:62-6.
3. Basaria S, Dobs AS. Hypogonadism and Androgen Replacement Therapy in elderly men. Am J Med 2001; 10:563-72.
4. Nieschlag E, Swerdloff R, Behre HM, et al. Investigation, Treatment and Monitoring of Late - Onset Hypogonadism in Males: ISA, ISSAM and EAU Recommendations. J Androl 2006; 27:135-7.
5. Vasan SS. Ageing Male and Testostrone: Current Status and Treatment Guidelines. I J U 2006; 22:15-22.
6. Morales A, Heaton JP, Carson CC. Andropause: A misnomer for a true clinical entitity. J Urol 2000; 163:705-12.
7. Vermeulen A. Androgen replacement therapy in the aging male-A critical evaluation. J Clin Endrocrinol Metab: 2001, 86: 2380-90.
8. Stas SN, Anastasiadis AG, Fisch H, Benson MC, ShabSigh R. Urologic aspects of andropause. Urology 2003; 61:261-6.
9. Gray A, Feldman HA, Mckinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle aged men: Results from the Massachusetts Male Aging study. J Clin Endocrinol Metab 1991; 73:1016-25.
10. Perry HM, Miller DK, Patrick P, Morley JE. Testosterone and leptin in older African-American men: relationship to age, strength, function and season. Metabolism 2000; 49:1085-91.
11. Leifke E, Gorenoi V, Wichers C, Muhlen A von Zur, Buren E Von, Brabant G. Age related changes of serum sex hormones, insulin like growth factor-1 and sex-hormone binding globulin levels in men: cross sectional data from a healthy cohort male. Clin Endrocrinol 2000; 53:689-95.
12. Anawalt BD, Merriam GR. Neurcendocrine aging in men. Andropause and Somatopause. Endocrinol Metab Clin North Am 2001; 30:647-69.
13. Jockenhorel F. Testosterone therapy - What. when and to whom? Aging male 2004; 7:319-24.
14. Lunenfeld B, Saaad F, Hoesl CE. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late- onset hypogonadism in males: Scientific background and rationale. Aging Male 2005; 8:59-74.
15. Morley JE, Charlton E, Patrick P, et al. Validation of a screening Questionnaire for androgen deficiency in aging males. Metabolism 2000; 49:1239-42.
16. Goncharov N, Katsya G, Dobracheva A, et al. Serum testosterone measurement in men: evaluation of modern immunoassay technologies. Aging Male 2005; 8: 194-202.
17. Lunenfiel B. Androgen therapy in the aging male. World J Urol. 2003; 21:293-305.
18. Rhoden EL, Morgentaler A. Risks of testosterone replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350:482-92.
19. Bhasin S, Buckwalter JG. Testosterone supplementation in older men: a rational idea whose time has not yet come. J Androl 2001; 22:718-31.
20. Hameed A, Brothwood T, Bouloux P. Delivery of testosterone replacement therapy. Curr Opin Invest Drugs 2003;4:1213-9.
21. Nitti VW, Sanders S, Staskin DR, et al. Transdermal delivery of drugs for urologic applications: Basic principles and applications. Urology 2006; 67: 657-64.
22. Hak AE, Wittenman JCM, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002; 87:3632-9.
23. Ebert T. Clinical experiences with testosterone therapy; prostate safety. Aging Male 2004;7:304-11.
24. Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate - specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002; 23: 922-6.
25. Tremblay RR, Morales A. Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. Aging male 1998; 1:213-8.
26. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risk of prostate disease during testosterone replacement therapy in older men. Recommendations for a standardized monitoring plan. J Androl 2003; 24:299-311.
27. Hanada K, Furuya K, Yamamoto N, et al. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM) in rat models of osteoporosis. Biol Pharm Bull 2003; 26: 1563-9.
28. Yin D, Gao W, Kearbey JD, et al. Pharmacodynamics of selective androgen receptor modulators (SARM). J pharacol Exp Ther 2003; 304: 1334-40.
29. Ebert T, Jockenhovel F, Morales A, Shabsigh R. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel. Eur Urol 2005; 47: 137-46.